Ensysce Biosciences closes $2 million financing tranche
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 7, 2026 8:14 AM EDT~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~
SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a second convertible preferred stock financing of $2 million under prior commitment in November 2025 of up to $20 million funding available over 24 months.
The capital will maintain Ensysce's flagship analgesic programs, while supporting general corporate... More
